Status:
UNKNOWN
Results of Endovascular Treatment for Infrapopliteal Arterial Occlusive Disease.
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
Peking University Third Hospital
Peking University First Hospital
Conditions:
Infrapopliteal Artery Occlusive Disease
Endovascular Treatment
Eligibility:
All Genders
18+ years
Brief Summary
This study is a prospective, multi-center observational study, which evaluates the effectiveness and safety of endovascular therapy in the real world for infrapopliteal arterial occlusive disease from...
Detailed Description
This study is a prospective, multi-center observational study. This study will be conducted at 38 centers and is expected to enroll more than 3000 patients. And we will evaluate the effectiveness and ...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age; Patients with ≥1 infrapopliteal artery disease (P3 popliteal artery, anterior tibial artery, posterior tibial artery, peroneal artery, tibiofibular trunk) need to receive endovascular treatment, regardless of whether there is a combination of supra-knee or submalleolar occlusion; Patients voluntary and capable of follow-up;
Exclusion
- Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc., and those who are unable to undergo endovascular therapy for other reasons; Pregnant and lactating women; Patients with thromboangiitis obliterans；
Key Trial Info
Start Date :
July 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06009146
Start Date
July 1 2023
End Date
October 1 2025
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053